About Outruntx
Outruntx is a company based in Dundee (United Kingdom) founded in 2021. Outruntx has raised $10 million across 1 funding round from investors including M-Ventures and MP Healthcare. Outruntx offers products and services including E3 Ligase Inhibitor Platform. Outruntx operates in a competitive market with competitors including Accutar Biotechnology, Plexium, Photys Therapeutics, Lycia Therapeutics and Uvic Steratics, among others.
- Headquarter Dundee, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Outrun Therapeutics Limited
- Date of Incorporation 26 Nov, 2019
- Jurisdiction DUNDEE, SCOTLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Seed
Apr 18, 2024
-
Investors
M-Ventures
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Outruntx
Outruntx offers a comprehensive portfolio of products and services, including E3 Ligase Inhibitor Platform.
Generates inhibitors for protein stabilisation in cancer treatment.
Funding Insights of Outruntx
Outruntx has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Seed round of $10 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Outruntx
Outruntx has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include M-Ventures and MP Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in multiple sectors
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life science innovations.
|
Locked | Locked | Locked |
Investor details for Outruntx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Outruntx
Investment portfolio details for Outruntx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Outruntx
Detailed financials for Outruntx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Outruntx Comparisons
Peer comparison for Outruntx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Outruntx
Outruntx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accutar Biotechnology, Plexium, Photys Therapeutics, Lycia Therapeutics and Uvic Steratics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-assisted tools for drug discovery are developed.
|
|
| Locked | Locked | Locked |
Integrated chemistry service provider
|
|
| Locked | Locked | Locked |
Protein-based small molecules are developed to treat human diseases.
|
|
| Locked | Locked | Locked |
Protein degradation drugs are developed for cancer and autoimmune diseases.
|
|
| Locked | Locked | Locked |
Anti-cancer drugs are developed via Proteolysis Targeting Chimera technology.
|
Detailed competitors of Outruntx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Outruntx
Complete news archive for Outruntx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Outruntx
Outruntx was founded in 2021 and raised its 1st funding round 3 years after it was founded.
Outruntx is headquartered in Dundee, United Kingdom. It is registered at Dundee, Scotland, United Kingdom.
Outruntx is a funded company, having raised a total of $10M across 1 funding round to date.
Outruntx was founded in 2021 and is based in Dundee, United Kingdom. Operations focus on the biotechnology sector, where therapeutics for cancer treatment are developed. A proprietary platform technology is utilized to identify compounds that selectively target the protein degradation pathway protecting tumor suppressors. This approach enables the treatment of cancer through targeted interventions.
Outruntx's top competitors include Plexium, Photys Therapeutics and Uvic Steratics.
Outruntx offers E3 Ligase Inhibitor Platform.
Outruntx has 2 investors. Key investors include M-Ventures, and MP Healthcare.